Tuberous Sclerosis Complex

Tuberous sclerosis complex is a genetic disorder characterized by benign tumors or hamartomas that can involve many organs, including the brain, skin, kidneys, heart, and lungs. The clinical picture can vary widely: some people have only mild skin findings, whereas in others seizures, developmental problems, kidney lesions, or behavioral effects are more prominent. For this reason, diagnosis and follow-up must be multidisciplinary. ^[1][2][3]

What is tuberous sclerosis complex?

Tuberous sclerosis complex is a neurocutaneous syndrome associated with changes in the TSC1 or TSC2 genes and can lead to multi-organ involvement. The lesions are usually benign, but depending on their location they can cause serious consequences such as seizures, hydrocephalus, kidney bleeding, lung problems, or learning and behavioral difficulties. For this reason, the phrase “benign tumor” does not mean the disease is mild; what matters most is which organ is affected and to what extent. ^[1][2][3]

Tuberous sclerosis complex may be present from birth, but not all findings appear at the same time. In some infants the first sign may be a cardiac rhabdomyoma or infantile spasms; in some children it may be skin findings; in some adults, renal angiomyolipomas may lead to diagnosis. Because of this broad phenotype, evaluation by a single specialty is usually not enough; neurology, dermatology, nephrology, genetics, child development, and when needed psychiatry should work together. ^[2][3]

What are the symptoms?

Commonly discussed findings include epileptic seizures, developmental delay, autism spectrum features, attention problems, hypomelanotic macules on the skin, facial angiofibromas, renal angiomyolipomas, and cardiac rhabdomyomas. Lung involvement is more often a concern in adult women. Not every patient develops all of these features; the clinical course is highly variable, which is why regular surveillance programs are critically important. ^[1][2][3]

The neurologic and neuropsychiatric dimensions of tuberous sclerosis are especially important. The term TAND, short for TSC-associated neuropsychiatric disorders, covers difficulties in behavior, attention, learning, mood, social communication, and daily functioning. Families often focus on visible skin findings, but school performance, speech development, sleep, behavior, and emotional regulation should be followed just as closely as organ lesions. ^[2][3]

How is it diagnosed?

Diagnosis is made by bringing clinical findings together and, when necessary, supporting them with genetic testing. Brain MRI, EEG, kidney imaging, skin examination, eye evaluation, and in some patients cardiac investigations can all be part of the diagnostic process. Early diagnosis matters not only for naming the condition, but also for seizure control, developmental support, and early detection of organ complications. ^[2][3]

In some children, the possibility of TSC is raised prenatally or in the newborn period when a cardiac rhabdomyoma is seen. In others, the first clue may be treatment-resistant seizures or white patches on the skin. Genetic testing can strengthen the diagnosis, but clinical evaluation remains fundamental. A negative test result does not entirely exclude the disease if clinical criteria are met, so decisions should be made by an experienced team. ^[2][3]

Core principles of treatment and follow-up

Treatment in tuberous sclerosis complex depends on which organ is affected. Antiseizure medications, and in some cases surgery or targeted treatments, may be used for seizures; renal lesions are followed with imaging and may require intervention; dermatologic treatments may be used for skin findings. Because the mTOR pathway plays an important role, targeted agents such as everolimus may be considered in selected patients, but this decision must always be made by a specialist team according to lesion type and patient characteristics. ^[2][3]

Follow-up is usually lifelong. Brain, kidney, skin, eye, and, when needed, lung assessments are repeated at set intervals. In children, developmental screening, speech and language evaluation, and educational support should be organized early. It is important to look not only at imaging results but also at sleep quality, school functioning, behavioral change, and caregiver burden. In the long term, quality of life is often determined not simply by the number of lesions but by the level of day-to-day functioning. ^[2][3]

Complications and when to seek medical care

Evaluation should not be delayed if there is an increase in seizure frequency, new vomiting or headache, changes in vision, blood in the urine, flank pain, shortness of breath, or marked behavioral change. These symptoms may point to very different problems, ranging from increased intracranial pressure to kidney complications or lung involvement. In children in particular, stagnation or regression in developmental milestones is an important warning sign. ^[2][3]

One of the most helpful approaches for families is a regular written follow-up plan. Management becomes safer when it is clear in advance which imaging should be performed at what age, what to do if a seizure occurs, how school support needs will be managed, and which symptoms require emergency care. This plan should be individualized, because TSC spans a broad spectrum, from mild skin findings to multi-organ involvement. ^[1][2][3]

In tuberous sclerosis complex, family education is not a passive add-on to treatment but an active part of it. Keeping a seizure diary, monitoring skin changes, noting fluctuations in behavior and sleep, and not missing scheduled imaging are all central to long-term care. Especially in young children, early intervention services, speech therapy, and preschool developmental support can markedly influence functional outcomes. For this reason, the idea that “check-ups are unnecessary if there are no symptoms” is not appropriate for TSC; silent organ involvement can also be detected only through regular surveillance. ^[2][3]

Tuberous sclerosis complex is a condition with effects too broad to be approached as a single-organ disease. The most appropriate strategy is to plan neurologic, developmental, dermatologic, and renal follow-up under one coordinated framework and to recognize new symptoms early. ^[2][3]